Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

CYP 450 2C19 polymorphisms in Indian patients with coronary artery disease.

Shetkar SS, Ramakrishnan S, Seth S, Chandna P, Verma SK, Bhargava B, Bahl VK.

Indian Heart J. 2014 Jan-Feb;66(1):16-24. doi: 10.1016/j.ihj.2013.10.001. Epub 2013 Nov 6.

2.

Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention.

Tang XF, Zhang JH, Wang J, Han YL, Xu B, Qiao SB, Wu YJ, Chen J, Wu Y, Chen JL, Gao RL, Yang YJ, Yuan JQ.

Chin Med J (Engl). 2013 Mar;126(6):1069-75.

PMID:
23506580
3.

Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.

Siller-Matula JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, Maurer G, Linkowska K, Grzybowski T, Huber K, Jilma B.

J Thromb Haemost. 2012 Apr;10(4):529-42. doi: 10.1111/j.1538-7836.2012.04639.x.

4.

No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.

Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, Mayer K, Bernlochner I, Schömig A, Kastrati A.

Eur Heart J. 2011 Jul;32(13):1605-13. doi: 10.1093/eurheartj/ehr155. Epub 2011 Apr 28.

PMID:
21527445
5.

CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.

Liu T, Yin T, Li Y, Song LQ, Yu J, Si R, Zhang YM, He Y, Guo WY, Wang HC.

Coron Artery Dis. 2014 Aug;25(5):412-20. doi: 10.1097/MCA.0000000000000092.

PMID:
24608794
6.

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.

Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH, Becker RC; PLATO investigators.

Lancet. 2010 Oct 16;376(9749):1320-8. doi: 10.1016/S0140-6736(10)61274-3.

PMID:
20801498
7.

Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.

Tsantes AE, Ikonomidis I, Papadakis I, Bonovas S, Gialeraki A, Kottaridi C, Kyriakou E, Kokori S, Douramani P, Kopterides P, Karakitsos P, Lekakis J, Kapsimali V.

Thromb Res. 2013 Aug;132(2):e105-11. doi: 10.1016/j.thromres.2013.06.015. Epub 2013 Jul 2.

PMID:
23830212
8.

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.

Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D.

BMJ. 2011 Aug 4;343:d4588. doi: 10.1136/bmj.d4588. Review.

10.

[Impact of cytochrome P450 2C19 polymorphisms on outcome of cardiovascular events in clopidogrel-treated Chinese patients after percutaneous coronary intervention].

Tang XF, He C, Yuan JQ, Meng XM, Yang YJ, Qin XW, Qiao SB, Liu HB, Wu YJ, Yao M, Chen J, You SJ, Wu Y, Li JJ, Dai J, Chen JL, Gao RL, Chen ZJ.

Zhonghua Xin Xue Guan Bing Za Zhi. 2011 Jul;39(7):617-20. Chinese.

PMID:
22088240
11.

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Valente S, Antoniucci D, Abbate R, Gensini GF.

Pharmacogenet Genomics. 2007 Dec;17(12):1057-64.

PMID:
18004210
12.
13.

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.

Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schömig A, von Beckerath N, Kastrati A.

Circulation. 2010 Feb 2;121(4):512-8. doi: 10.1161/CIRCULATIONAHA.109.885194. Epub 2010 Jan 18.

15.

Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome.

Cuisset T, Quilici J, Cohen W, Fourcade L, Saut N, Pankert M, Gaborit B, Carrieri P, Morange PE, Bonnet JL, Alessi MC.

Am J Cardiol. 2011 Sep 15;108(6):760-5. doi: 10.1016/j.amjcard.2011.05.045. Epub 2011 Jul 30.

PMID:
21803320
16.

Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms.

Kar R, Meena A, Yadav BK, Yadav R, Kar SS, Saxena R.

Platelets. 2013;24(4):297-302. doi: 10.3109/09537104.2012.693992. Epub 2012 Jun 21.

PMID:
22721490
17.

Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.

Hochholzer W, Trenk D, Fromm MF, Valina CM, Stratz C, Bestehorn HP, Büttner HJ, Neumann FJ.

J Am Coll Cardiol. 2010 Jun 1;55(22):2427-34. doi: 10.1016/j.jacc.2010.02.031.

18.

The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease.

Xie C, Ding X, Gao J, Wang H, Hang Y, Zhang H, Zhang J, Jiang B, Miao L.

Pharmacogenet Genomics. 2014 Apr;24(4):204-10. doi: 10.1097/FPC.0000000000000035.

PMID:
24535487
19.

CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention.

Mejin M, Tiong WN, Lai LY, Tiong LL, Bujang AM, Hwang SS, Ong TK, Fong AY.

Int J Clin Pharm. 2013 Aug;35(4):621-8. doi: 10.1007/s11096-013-9783-y. Epub 2013 May 10.

PMID:
23661171
20.

Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.

Maeda A, Ando H, Asai T, Ishiguro H, Umemoto N, Ohta M, Morishima M, Sumida A, Kobayashi T, Hosohata K, Ushijima K, Fujimura A.

Clin Pharmacol Ther. 2011 Feb;89(2):229-33. doi: 10.1038/clpt.2010.268. Epub 2010 Dec 22.

PMID:
21178986

Supplemental Content

Support Center